Stem cell and kinase activity-independent pathway in resistance of leukaemia to BCR-ABL kinase inhibitors.

Journal of Cellular and Molecular Medicine
Shaoguang Li, Dongguang Li

Abstract

BCR-ABL tyrosine kinase inhibitors, such as imatinib (Gleevec) are highly effective in treating human Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) in chronic phase but not in terminal acute phase; acquired drug resistance caused mainly by the development of BCR-ABL kinase domain mutations prevents cure of the leukaemia. In addition, imatinib is ineffective in treating Ph+ B-cell acute lymphoblastic leukaemia (B-ALL) and CML blast crisis, even in the absence of the kinase domain mutations. This type of drug resistance that is unrelated to BCR-ABL kinase domain mutations is caused by the insensitivity of leukaemic stem cells to kinase inhibitors such as imatinib and dasatinib, and by activation of a newly-identified signalling pathway involving SRC kinases that are independent of BCR-ABL kinase activity for activation. This SRC pathway is essential for leukaemic cells to survive imatinib treatment and for CML transition to lymphoid blast crisis. Apart from BCR-ABL and SRC kinases, stem cell pathways must also be targeted for curative therapy of Ph+ leukaemia.

References

Jul 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·E FeinsteinE Canaani
Sep 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·M A KelliherN Rosenberg
Apr 1, 1996·The Journal of Experimental Medicine·M A GoodellR C Mulligan
Jan 6, 1999·Proceedings of the National Academy of Sciences of the United States of America·N TakedaY Maru
Apr 29, 1999·The New England Journal of Medicine·C L Sawyers
Sep 4, 1999·The New England Journal of Medicine·I Nash
Dec 30, 1999·Nature Genetics·C S HuettnerD G Tenen
Mar 27, 2001·Blood·E DeutschJ Bourhis
Apr 5, 2001·The New England Journal of Medicine·B J DrukerC L Sawyers
Oct 31, 2001·Molecular Cell·A SlupianekT Skorski
Nov 2, 2001·Nature·T ReyaI L Weissman
Mar 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael C HeinrichChristopher L Corless
Aug 1, 2002·Proceedings of the National Academy of Sciences of the United States of America·Sergei RoumiantsevRichard A Van Etten
Mar 6, 2003·Oncogene·Joyce A SchroederSandra J Gendler
Apr 30, 2003·Nature·Tannishtha ReyaIrving L Weissman
Jun 11, 2003·Recent Progress in Hormone Research·Tannishtha Reya
Jan 7, 2004·Biochemical and Biophysical Research Communications·Keiko HaraguchiTetsu Akiyama
Feb 26, 2004·Blood·Bruno Calabretta, Danilo Perrotti
May 1, 2004·Nature Genetics·Michael Deininger
Jul 17, 2004·Science·Neil P ShahCharles L Sawyers
Aug 13, 2004·The New England Journal of Medicine·Catriona H M JamiesonIrving L Weissman
Aug 28, 2004·Expert Opinion on Investigational Drugs·Sheila A Doggrell
Oct 27, 2004·Proceedings of the National Academy of Sciences of the United States of America·S WongO N Witte
Nov 6, 2004·Blood·Lucy J ElrickTessa L Holyoake

❮ Previous
Next ❯

Citations

Jan 7, 2011·Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society·Heather O'LearyLaura F Gibson
Sep 19, 2008·Leukemia·N MisaghianJ A McCubrey
Aug 29, 2009·Medicinal Research Reviews·S SchenoneM Botta
Feb 6, 2010·Stem Cells·Frank PajonkWilliam H McBride

❮ Previous
Next ❯

Related Concepts

Related Papers

The International Journal of Biochemistry & Cell Biology
Shaoguang Li
The New England Journal of Medicine
Moshe TalpazCharles L Sawyers
© 2021 Meta ULC. All rights reserved